Breaking News

ICON Implements Informatica MDM

By Kristin Brooks | March 6, 2014

Integration software aims to improve access to business-critical data

ICON plc has selected Informatica Corp. to improve its clinical trials and development process by implementing the multi-domain Informatica MDM solution, which creates a consolidated view of business-critical data, such as investigators and sites, and the relationships between the data. This strategy aims to improve the potential of ICON's data for faster, better-informed decisions, including clinical trial planning, trial execution services and improved reporting.

Andrew Thompson, vice president of technology, ICON, said, "Our business is all about data. Informatica unlocks the potential of ICON's data, delivering 360-degree insights into, study and site related program activities. This enables the company to continuously monitor the clinical trials process, optimize operations based on real-time alerts and data insights and mitigate risk. The ultimate outcome is increased productivity."

Dennis Moore, senior vice president and general manager of MDM at Informatica says, "In today's hyper-competitive and rapidly evolving healthcare market, accurate information and effective drug discovery and clinical trials are the lifeblood of life sciences companies. To succeed, life sciences organizations need an enterprise view of compound research across current and previous trials. Informatica MDM delivers that single, 360-degree view of the clinical trials program, enabling companies like ICON to increase efficiency and reduce costs."

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems